Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences
SNSE 10.29.2024
Date of Upcoming Event:2024-11-05
Name of Upcoming Event:PEGS Europe: Protein and Antibody Engineering Summit
Date of Upcoming Event:2024-11-09
Name of Upcoming Event:Society for Immunotherapy Cancer (SITC) 39th Annual Meeting
About Gravity Analytica
Recent News
- 01.08.2025 - Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
- 11.27.2024 - Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference
- 11.14.2024 - Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Recent Filings
BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the Company will present at two upcoming scientific conferences.
Conference and Presentation Details:
PEGS Europe: Protein and Antibody Engineering Summit, November 5-7, 2024, Barcelona, Spain
Title:Selectively Targeting VISTA in the Tumor-Microenvironment with SNS-101, a Conditionally Active Monoclonal AntibodyPresenter:Edward van der Horst, Ph.D., Chief Scientific OfficerSession:Antibody-Based Cancer TherapiesDate and time:Tuesday, November 5, 2024, 9:00 a.m. CET (Central European Time)
Society for Immunotherapy Cancer (SITC) 39thAnnual Meeting, November 6-10, Houston Texas
Title:Spatial proteomic profiling of VISTA and PSGL-1 interactions across cancer indicationsPresenter:F. Donelson Smith, Ph.D., Senior Director, Biologics Discovery & Early DevelopmentPresentation Type:PosterAbstract Number:70Date and Time:Saturday, November 9, 2024, 12:15–1:45 p.m. & 7:00-8:30 p.m. CST.Location:Level 1-Exhibit Halls AB (George R. Brown Convention Center)
About Sensei BiotherapeuticsSensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAbTM (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visitwww.senseibio.com, and follow the company on X @SenseiBio andLinkedIn.
Investor Contact:Michael BiegaSenior Director, Investor RelationsSensei Biotherapeuticsmbiega@senseibio.com
Media Contact:Joyce AllaireLifeSci AdvisorsJallaire@lifesciadvisors.com
